Effects of first-line nucleot(s)ide analogues on lipid profiles in patients with chronic hepatitis B: a network meta-analysis-Reference-Cited by-同舟云学术

Effects of first-line nucleot(s)ide analogues on lipid profiles in patients with chronic hepatitis B: a network meta-analysis

Published:2024-01-10 Issue:3 Volume:80 Page:335-354
ISSN:0031-6970
Container-title:European Journal of Clinical Pharmacology
language:en
Short-container-title:Eur J Clin Pharmacol

Author:

Tong Kexin^ORCID,Chen Mingjing,Wang Danni,Dai Haifeng,Peng Jiayi,Zhang Jia,Zhou Jiao,Chang Yujiao,Huang Wenxiang^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00228-023-03616-y.pdf

Reference68 articles.

1. World Health Organization (2021) Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021: accountability for the global health sector strategies 2016–2021: actions for impact. https://apps.who.int/iris/handle/10665/341412. Accessed July 7 2023

2. Choi HSJ, Tonthat A, Janssen HLA et al (2022) Aiming for functional cure with established and novel therapies for chronic hepatitis B. hepatol Commun6(5):935–949. https://doi.org/10.1002/hep4.1875

3. Chinese Society of Hepatology CMA (2022) Guidelines for the prevention and treatment of chronic hepatitis B (version 2022). Chinese J hepatol 30(12):1309–1331. https://doi.org/10.3760/cma.j.cn501113-20221204-00607

4. Mach F, Baigent C, Catapano AL et al (2020) 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur heart J 41(1):111–188. https://doi.org/10.1093/eurheartj/ehz455

5. Mena Á, Pedreira JD, Castro Á et al (2014) Metabolic syndrome association with fibrosis development in chronic hepatitis B virus inactive carriers. J Gastroenterol Hepatol 29(1):173–178. https://doi.org/10.1111/jgh.12432